[A clinical study on cefteram pivoxil in pediatrics]

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Antimicrobial Therapy

Context:

• Pediatric infections pose a significant health challenge, necessitating effective and safe treatment options.
• Cefteram pivoxil (CFTM-PI) is an antibiotic evaluated for its therapeutic potential in pediatric populations.
• Understanding the clinical efficacy and safety of CFTM-PI is crucial for its appropriate use.

Purpose:

• To evaluate the clinical efficacy of cefteram pivoxil in pediatric patients with various infections.
• To assess the bacteriological eradication rates of CFTM-PI against common pediatric pathogens.
• To determine the safety and tolerability profile of cefteram pivoxil in children.

Summary:

• Clinical evaluations of cefteram pivoxil (CFTM-PI) in 39 pediatric patients showed an overall efficacy rate of 94.9% (16 excellent, 21 good, 1 fair, 1 poor).
• Bacteriological assessment revealed high eradication rates: 94.1% for Gram-positive cocci (17 strains) and 90.9% for Gram-negative rods (22 strains).
• Adverse events were infrequent (8.7%), including mild gastrointestinal issues and skin reactions; one case of eosinophilia was noted.

Impact:

• The findings suggest cefteram pivoxil is a highly effective and safe therapeutic option for treating pediatric infections.
• CFTM-PI's broad spectrum of activity and favorable safety profile support its consideration in pediatric infectious disease management.
• This study contributes valuable data for clinicians and researchers regarding the use of CFTM-PI in pediatric care.